Frontline Treatment Patterns for Multiple Myeloma Similar for Black, White Patients

Frontline treatments patterns were similar among patients with multiple myeloma (MM) of different race in a contemporary real-world cohort, but African American patients did experience some delays in initiation of frontline treatment.

Data from this study of 1,790 patients, including 296 African Americans, from the COTA real-world database were presented at the 2021 International Myeloma Workshop. All patients had an active MM diagnosis after January 2015.

The African American cohort of patients were younger (median age 61.0 vs. 66.0 years; P<0.001) and had more female patients (52.4% vs. 40.9%; P<0.001) compared with the White cohort of patients. The majority of patients in both groups were treated in the academic setting.

The median time to firstline treatment was significantly longer for African American patients compared with White patients (24.0 vs. 19.0 days; P=0.002). Time to first stem cell transplant was also longer (218.0 vs. 185.0 days, respectively; P<0.001).

The types of frontline treatments were similar across racial cohorts. The most common frontline treatment was a proteasome inhibitor (PI) combined with an immunomodulator (IMiD) and steroids. Similarly, 13.9% of African American patients and 15.9% of White patients received frontline stem cell transplant.

Among those patients that received a frontline PI, 80.0% of African American patients received a bortezomib-based regimen compared with 71.3% of White patients, and 16.9% received a carfilzomib regimen compared with 23.8% of White patients (P = 0.03).  No racial differences in time to next treatment were found.

“Future analyses will investigate treatment patterns by practice setting and expand into later lines of treatment to further elucidate if academic practices and uniform treatment patterns drive similar outcomes by race,” the researchers wrote.

These data are from Abstract P-119 “Evaluation of real-world frontline treatment for multiple myeloma by race,” presented at IMW 2021, September 8-11, 2021.